The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Xiaoyu Lv; Hui Wang; Chongyang Chen; Yangting Zhao; Kai Li; Yawen Wang; Liting Wang; Songbo Fu; Jingfang Liu

doi:10.2147/DMSO.S443396

The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Diabetes Metab Syndr Obes. 2024 Feb 12:17:701-714. doi: 10.2147/DMSO.S443396. eCollection 2024.

Authors

Xiaoyu Lv¹, Hui Wang¹, Chongyang Chen¹, Yangting Zhao¹, Kai Li¹, Yawen Wang¹, Liting Wang^{1

2}, Songbo Fu^{1

2}, Jingfang Liu^{1

2}

Affiliations

¹ The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
² Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China.

Abstract

Aim: To explore the effects of Tirzepatide (TZP), a new hypoglycemic drug, on weight, blood lipids and blood pressure in overweight/obese patients with type 2 diabetes mellitus (T2DM).

Methods: Relevant studies investigating the influence of TZP therapy on weight, lipid profiles and blood pressure in overweight/obese T2DM patients were selected from the PubMed, Embase, Web of Science and Cochrane databases from establishment until November 2022. A systematic review and meta-analysis were conducted to evaluate the effect of TZP on weight, blood lipids and blood pressure in overweight/obese patients with T2DM.

Results: Eight randomized controlled trials (RCTs), comprising 7491 patients with T2DM, were included in the meta-analysis. Results showed that compared with the glucagon-like peptide-1 receptor agonist (GLP-1RA), insulin, and placebo groups, body weight, triglycerides (TG), very low-density lipoprotein cholesterol (VLDL-C), total cholesterol (TC), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), and glycosylated hemoglobin (HbA1c) levels were significantly decreased in the TZP-treated groups, while high-density lipoprotein cholesterol (HDL-C) levels increased. With the gradual increase of TZP doses, the proportions of T2DM patients with weight loss >5% gradually increased. The 10 mg and 15 mg TZP doses had a stronger effect on the levels of TG, VLDL-C, and HDL-C. Moreover, the reduction in SBP levels in the 15 mg TZP-treated group was more pronounced than those in the 10 mg and 5 mg TZP-treated groups [MD=-2.07, 95% CI (-2.52, -1.63) and MD=-3.14, 95% CI (-4.42, -1.87)]. Compared with GLP-1RA, insulin, and placebo groups, the proportions of patients with HbA1c<7% in 10mg and 15mg TZP-treated groups were significantly higher than in the 5mg TZP-treated group [OR=1.53, 95% CI (1.25, 1.8)], OR=1.7, 95% CI (1.15, 2.50)].There was no significant difference regarding the risk of adverse reactions.

Keywords: T2DM; lipid metabolism; meta-analysis; tirzepatide; weight.

Publication types

Review

Grants and funding

This study was funded by the National Natural Science Foundation of China (No.81960155), Natural Science Foundation of Gansu Province (20JR10RA690) and The Hospital Fund of the First Hospital of Lanzhou University (ldyy-2021-01).